Biology today: Notch, Zocdoc and Koa Health
GeneQuine Biotherapeutics Raises Over Euro 9M in Series A and Non-Dilutive Funding
GeneQuine Biotherapeutics GmbH, a Hamburg, Germany-based biotech company focused on the development of gene therapy for musculoskeletal disorders, raised €5.4m in Series A financing and €3.65m non-dilutive funding bringing the total amount raised to €9.05m.
The round was led by Pacira BioSciences, Inc. (Nasdaq: PCRX), with participation from High-Tech Gründerfonds, Noshaq SA, and Samum Vermögensverwaltungs GmbH.
The company intends to use the funds to advance its lead candidate GQ-303 for osteoarthritis (OA) to a phase 1 clinical trial, to develop new gene therapies for the treatment of intervertebral disc degeneration, to expand its gene therapy vector platform and to grow operations.
GeneQuine Biotherapeutics Raises Over Euro 9M
GeneQuine Biotherapeutics, a Hamburg, Germany-based biotech company focused on the development of gene therapy for musculoskeletal disorders, raised €9.05m
Kranus Health Raises Seven-Figure Seed Funding
Kranus Health, a Munich, Germany-based digital men’s health platform, raised a seven-figure seed funding round.
Backers included HTGF, A Round Capital, Venture Basecamp and Dr. Ralph Müller and existing business angels Konstantin Mehl (founder Foodora + Kaia Health).
The company intends to use the funds to further expand its men’s health platform, launch a reimbursable digital therapy as long-term solution for Erectile Dysfunction and create new solutions.
Kranus Health Raises Seven-Figure Seed Funding | FinSMEs
Kranus Health, a Munich, Germany-based digital men’s health platform, raised a seven-figure seed funding round
SpyBiotech Raises $32.5M in Series A Funding
SpyBiotech, an Oxford, United Kingdom-based biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, raised $32.5m in Series A equity financing.
The round was led by new investor Braavos Investment Advisers and joined by new investor Oxford Investment Consultants. Founding investors Oxford Sciences Innovation and GV also participated, alongside the UK Government’s Future Fund, converting a prior convertible loan into equity.
The company intends to use the funds to advance the clinical development of its novel vaccine technology platform planning to begin a Phase I clinical study of its internal lead candidate, targeting human cytomegalovirus (HCMV), in early 2022.
SpyBiotech Raises $32.5M in Series A Funding | FinSMEs
SpyBiotech, an Oxford, United Kingdom-based biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, raised $32.5m in Series A equity financing
Barcelona-based Koa Health extends Series A round to €30 million
Koa Health, a Barcelona-based digital mental healthcare provider, has announced it closed an oversubscribed €30 million Series A funding round.
Investors in the final close include MTIP and Akilia Partners, Creas Impacto, Sabadell Asabys and Mundi Ventures.
The company’s lead product is Koa Foundations, a mental wellbeing app that helps organisations better support employees with a library of evidence-based activities focused on tackling stress, sleeping better, etc. According to a press release, the app is available to over three million people through contracts with dozens of employers, healthcare providers and payers.
Much of the new capital will go to product development, including expanding the diagnoses that Koa’s solutions can support, adding more wellness content, and making programs available in new languages. This includes bolstering R&D to further its investment in technology that powers personalised care.
The company will also use this new funding to break into international markets, including North America.
Barcelona-based Koa Health extends Series A round to €30 million – Tech.eu
Koa Health, a Barcelona-based digital mental healthcare provider, has announced it closed an oversubscribed €30 million Series A funding round. The round had a first close last fall, when the […]
InteRNA Technologies Extends Series B Financing Round Totaling €18.5M
InteRNA Technologies, an Utrecht, The Netherlands-based company that designs new therapies tackling cancer, closed an extended Series B financing round amounting to €18.5M in total.
This Series B round was led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures. Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round.
The funding will enable the clinical evaluation of the company’s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors. Furthermore, the proceeds will be used to develop and advance additional proprietary preclinical drug candidates adressing a variety of cancer indications thereby expanding InteRNA’s pipeline. As part of the Series B financing, Gabriele Campi, PhD, of AurorA Science will join the Board of Directors.
InteRNA Technologies Extends Series B Financing Round Totaling €18.5M
InteRNA Technologies, an Utrecht, The Netherlands-based company that designs new therapies tackling cancer, closed an extended Series B financing round amounting to €18.5M in total
Grapheal Raises EUR 1.9M to in Funding
Grapheal, a Grenoble, France-based developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, raised a total of EUR1.9m in equity and non-dilutive sources.
This includes seed financing from Novalis Biotech’s Acceleration Fund, several innovation grants, and Bpifrance convertible notes and loans.
The funds will be used to advance the industrialization of the company’s flexible graphene-based biosensor technology and to validate the two devices in the field and complete clinical studies, respectively. The company’s sensing technology combines novel electronic nanomaterials, embedded wireless electronics, software data analysis, and medical cloud IoT technologies.
Grapheal Raises EUR 1.9M to in Funding | FinSMEs
Grapheal, a Grenoble, France-based developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, raised a total of EUR1.9m in equity and non-dilutive sources
Zocdoc Raises $150M in Growth Financing
Zocdoc, a NYC-based digital healthcare marketplace, raised $150m in growth financing.
Francisco Partners made the investment.
The company will use the capital to further accelerate growth, deepening its investments in sales and marketing, and expanding the products available through its platform.
Led by Oliver Kharraz, M.D., founder and CEO, Zocdoc is a digital healthcare marketplace for in-person or virtual care. Each month, millions of patients use its free service, via the web site or the app, to find in-network doctors, instantly book in-person or virtual appointments, read reviews from verified patients, get reminders for upcoming appointments and preventive checkups, and more.
Zocdoc Raises $150M in Growth Financing | FinSMEs
Zocdoc, a NYC-based digital healthcare marketplace, raised $150m in growth financing. Francisco Partners made the investment.
Notch Therapeutics Closes $85M Series A Financing
Notch Therapeutics, Inc., a Vancouver, BC-based biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, closed an U.S. $85m Series A financing.
The round was led by an exclusively healthcare-focused investment fund.
The company intends to use the funds for the continuing development of its portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company’s proprietary Engineered Thymic Niche (ETN) platform, to expand its team to support future growth, including establishing operations in Seattle, in addition to the company’s existing operations in Vancouver and Toronto.